Introducing Benchling Biologics: AI infrastructure for modern drug discovery (Americas Session)

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing.

In this webinar on 11 June 2026, hosted by DDW, Lily Helfrich from Benchling will cover the shifting antibody discovery landscape and the scientific fundamentals behind a modern data foundation for complex biologics – for everything from mAbs to complex multispecifics and fusion proteins.

You’ll also hear firsthand how Benchling customers are tackling these challenges: what’s driving decisions to modernise, what’s working, and lessons learned along the way.Finally, we’ll show you Benchling Biologics: an antibody-aware data model, no-code format configuration, and automated registration that connects sequences to proteins to experimental context. Whether you’re modernising legacy registration, scaling antibody programmes, or preparing your data for AI/ML, you’ll leave with practical takeaways.